03/01 | Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical S.. |  |
02/01 | Valneva's COVID-19 Booster Shot Shows Only Marginally Higher Neutralizing Antibody Resp.. |  |
2022 | Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine |  |
2022 | Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine |  |
2022 | Certain Stock Options of Valneva SE are subject to a Lock-Up Agreement Ending on 29-DEC.. |  |
2022 | Certain Equity Warrants of Valneva SE are subject to a Lock-Up Agreement Ending on 29-D.. |  |
2022 | Certain Ordinary Shares of Valneva SE are subject to a Lock-Up Agreement Ending on 29-D.. |  |
2022 | Sector Update: Health Care Stocks Mixed Premarket Friday |  |
2022 | Fresh Inflation Data Eyed as Exchange-Traded Funds, Equity Futures Edge Higher Premarke.. |  |
2022 | Valneva Says it Completed Rolling US Regulatory Submission for One-Shot Chikungunya Vac.. |  |
2022 | Bolsa de Madrid: Todavía en modo ciclotímico |  |
2022 | Valneva Finalizes Biologics License Submission With US FDA For Chikungunya Vaccine |  |
2022 | Valneva makes U.S. regulatory submission for one-shot chikungunya vaccine |  |
2022 | Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Ca.. |  |
2022 | Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Ca.. |  |
2022 | Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Ca.. |  |
2022 | Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and O.. |  |
2022 | Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and O.. |  |
2022 | Valneva COVID-19 Vaccine Reportedly Not Recommended by French Regulator |  |
2022 | French Public Health Body Snubs Valneva in COVID-19 Vaccine Strategy |  |
2022 | Valneva shares fall as French health body advises against its COVID-19 vaccine |  |
2022 | Valneva : Advances in the development of a single-shot live-attenuated chikungunya vaccine.. |  |
2022 | Valneva SE Reiterates Revenue Guidance for the Year 2022 |  |
2022 | Valneva : Whole-cell inactivated platforms (Valneva Breakfast Symposium Presentation at th.. |  |
2022 | Inactivated Whole Cells Platform : the importance of choosing the right adjuvant, as illus.. |  |
2022 | Valneva Hosts Investor Day in New York City |  |
2022 | Valneva Hosts Investor Day in New York City |  |
2022 | EMA Publishes Updated Information On COVID-19 Vaccine Valneva, With Increase In Its App.. |  |
2022 | Ema: ema published updated information on covid-19 vaccine valne… |  |
2022 | Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday |  |
2022 | Sector Update: Health Care |  |
2022 | Valneva Says Chikungunya Vaccine Candidate Shows 99% Seroresponse Rate After 12 Months |  |
2022 | Valneva Shares Gain After Positive Vaccine Trial Results |  |
2022 | EN DIRECTO DESDE LOS MERCADOS: Amazon, Apple, Valneva, Bén.. |  |
2022 | Valneva To Complete US FDA Application For Chikungunya Vaccine Candidate By 2022-end |  |
2022 | Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya.. |  |
2022 | Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya.. |  |
2022 | Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya.. |  |
2022 | Strong Eurozone Manufacturing Data Pushes European Bourses to Close Mostly Higher |  |
2022 | Pfizer, Valneva Say Lyme Disease Vaccine Candidate Shows Antibody Levels Remain Above B.. |  |
2022 | Valneva, Pfizer Tout Six-month Antibody Persistence Data for Lyme Disease Vaccine Candi.. |  |
2022 | Valneva-Pfizer's Lyme Disease Jab Continues To Provide Protection Six Months Post-vacci.. |  |
2022 | Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults fo.. |  |
2022 | Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults fo.. |  |
2022 | Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults fo.. |  |
2022 | Valneva to Host Investor Day in New York City |  |
2022 | Valneva to Host Investor Day in New York City |  |
2022 | Vaccine Developer Valneva Appoints New Chief Commercial Officer |  |
2022 | Valneva Appoints Dipal Patel as Chief Commercial Officer |  |
2022 | Valneva Appoints Dipal Patel as Chief Commercial Officer |  |
2022 | ValnevaSE Appoints Dipal Patel as Chief Commercial Officer |  |
2022 | Jobkahlschlag bei Corona-Impfstoffhersteller Valneva |  |
2022 | Valneva Plans Workforce Reduction of Up to 25% in Restructuring Move |  |
2022 | Bolsa de Madrid: ¿Feliz cumpleaños, bitcoin? |  |
2022 | French drugmaker Valneva to cut 20%-25% of workforce |  |
2022 | Valneva SE Reports Earnings Results for the Nine Months Ended September 30, 2022 |  |
2022 | Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates |  |
2022 | Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates |  |
2022 | Valneva SE Reiterates Earnings Guidance for the Fiscal 2022 |  |
2022 | Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Confer.. |  |
2022 | Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Confer.. |  |
2022 | Chikungunya : Phase 3 Clinical Development of a Single-shot Live-Attenuated Vaccine (Prese.. |  |
2022 | One Step Closer To A Chikungunya Vac : update on Valneva's live-attenuated vaccine candida.. |  |
2022 | Europäische Staatsanwaltschaft untersucht Kauf der Corona-Impfstoffe |  |
2022 | One Step Closer To A Chikungunya Vac : update on Valneva's live-attenuated vaccine candida.. |  |
2022 | Bolsa de Madrid: Un rebote semanal engañoso |  |
2022 | Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientif.. |  |
2022 | Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientif.. |  |
2022 | Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientif.. |  |
2022 | Bolsa de Madrid: Los planetas se alinean a toda prisa |  |
2022 | Valneva Raises $103 Million to Advance Lyme Disease, Chikungunya Vaccine Candidates; Sh.. |  |
2022 | Valneva Announces Closing of Upsized €102.9 Million Global Offering |  |
2022 | Valneva Announces Closing of Upsized €102.9 Million Global Offering |  |
2022 | Valneva : Document AMF CP. 2022E864499 |  |
2022 | Valneva : Document AMF CP. 2022E864246 |  |
2022 | Valneva Prices Upsized Global Offering of $99.9 Million of Ordinary Shares and ADSs |  |
2022 | Bolsa de Madrid: Inversores en posición lateral de seguridad |  |
2022 | Valneva Prices Upsized $101 Million Global Offering to Fund Vaccines Developments |  |
2022 | Valneva Announces Pricing of €102.9 Million Global Offering of American Depositary Shar.. |  |
2022 | Valneva Announces Pricing of €102.9 Million Global Offering of American Depositary Shar.. |  |
2022 | Valneva SE announced that it expects to receive funding from Deep Track Capital, LP |  |
2022 | Sector Update: Health Care Stocks Decline Pre-Bell Thursday |  |
2022 | Valneva to Raise $40 Million via Global Offering |  |
2022 | Valneva Plans $40 Million Capital Raise From Global Share Offering |  |
2022 | Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of .. |  |
2022 | Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of .. |  |
2022 | Valneva Says It Is in Active Discussions With Prospective Partner to Develop Second-Gen.. |  |
2022 | Bolsa de Madrid: El elefante en la habitación |  |
2022 | Valneva In Talks With Potential Partner For Development Of Second-generation COVID-19 V.. |  |
2022 | Valneva in talks with potential partner on second-gen COVID-19 vaccines |  |
2022 | Talks on second-gen COVID vaccine could fail, Valneva warns |  |
2022 | Valneva Provides Further Update on its COVID-19 Activities |  |
2022 | Valneva Provides Further Update on its COVID-19 Activities |  |
2022 | Bolsa de Madrid: No está yendo muy bien |  |
2022 | Valneva : Document AMF CP. 2022E862347 |  |
2022 | Valneva : Document AMF CP. 2022E861835ANN |  |
2022 | Valneva : Document AMF CP. 2022E861835 |  |
2022 | Aktien Europa: Schwächer - Immobilienwerte unter Druck |  |
2022 | Sector Update: Health Care Stocks Largely Resist Late Buying Support |  |
2022 | Sector Update: Health Care Stocks Retreating to Begin New Week |  |